S-1: Virpax Pharmaceuticals Eyes $14 Million in Best Efforts Offering to Fund Operations and Settle Litigation

Virpax Pharmaceuticals launches a best efforts offering of common stock and warrants, aiming to raise up to $14 million to support product development, settle legal obligations, and bolster working capital.

Summary

• Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company, is undertaking a best efforts offering to sell shares of its common stock and accompanying warrants.
• The offering aims to raise up to $14 million, with proceeds intended to cover a $2.5 million litigation settlement payment, fund product development, and support general corporate purposes.
• The offering includes common stock, pre-funded warrants (in lieu of common stock for certain purchasers), and common warrants to purchase common stock.
• A.G.P./Alliance Global Partners is acting as the exclusive placement agent for the offering.
• The offering is set to terminate on May 25, 2024, unless fully subscribed or terminated earlier by the company.
• The company recently underwent a 1-for-10 reverse stock split and settled litigation with Sorrento Therapeutics and Scilex Pharmaceuticals for $6 million plus royalties.
• Virpax Pharmaceuticals is focused on developing novel drug delivery systems for pain management and CNS disorders.
• The company has received a notification from Nasdaq regarding non-compliance with minimum stockholders' equity requirements for continued listing.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is raising capital and settling litigation, it also faces financial challenges and Nasdaq compliance issues. The best efforts nature of the offering adds uncertainty.

Positives

• The offering provides capital to settle a significant legal obligation and fund ongoing product development.
• The company has exclusive global rights to several proprietary patented technologies.
• The company is exploring value creative opportunities for nonprescription product candidates.
• Settlement Agreement and Mutual Release with Sorrento and Scilex fully resolves all claims against the Company related to the litigation.

Negatives

• The company has a limited operating history and expects to incur significant operating losses for the foreseeable future.
• The company needs additional financing to file its Investigational New Drug Application (IND) for Probudur.
• The company received a notification from Nasdaq regarding non-compliance with minimum stockholders' equity requirements.
• The company may sell fewer than all of the securities offered, which may significantly reduce the amount of proceeds received.
• The company has broad discretion in using the net proceeds from this offering.
• The offering may cause the trading price of the company's common stock to decrease.
• There is no public market for the pre-funded warrants and common warrants being offered.

Risks

• The company will need additional future financing which may not be available on acceptable terms, if at all and will result in the issuance of additional securities being issued which will cause investors to experience further dilution.
• The company's management has broad discretion in using the net proceeds from this offering.
• This is a reasonable best efforts offering, with no minimum amount of Securities required to be sold, and the company may sell fewer than all of the Securities offered hereby.
• If you purchase shares of the company's Common Stock sold in this offering, you will experience immediate and substantial dilution in the net tangible book value of your shares.
• The company's failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a de-listing of the company's common stock.

Future Outlook

The company intends to use the net proceeds from this offering to pay the $2.5 million that it is obligated to pay to the Plaintiffs pursuant to the Settlement Agreement and for working capital and other general corporate purposes. The company expects to require an additional $11.0 million in order to file its IND for Probudur, including the $2.5 million that it is obligated to pay to the Plaintiffs. Therefore, even if the company sells the maximum number of Securities, it will need to raise additional capital in order to file its IND.

Industry Context

Virpax Pharmaceuticals operates in the competitive preclinical-stage pharmaceutical industry, focusing on novel drug delivery systems for pain management and CNS disorders. The company's success depends on its ability to develop and commercialize its product candidates, navigate regulatory hurdles, and secure additional funding.

Comparison to Industry Standards

• Virpax Pharmaceuticals is a preclinical-stage company, making direct comparisons to revenue-generating pharmaceutical companies difficult.
• Comparable companies in the preclinical stage often rely on venture capital, partnerships, or initial public offerings (IPOs) for funding.
• The company's focus on non-opioid pain management aligns with a growing industry trend towards safer and non-addictive pain relief solutions.
• The company's reliance on proprietary patented technologies is a common strategy in the pharmaceutical industry to protect intellectual property and gain a competitive advantage.
• The company's recent settlement of litigation is a common occurrence in the pharmaceutical industry, where intellectual property disputes and patent challenges are frequent.

Legal Proceedings

• The company entered into a Settlement Agreement and Mutual Release with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. to fully resolve all claims by the Plaintiffs against the Company related to the litigation captioned Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. v. Anthony Mack and Virpax Pharmaceuticals, Inc., Case No. 2021-0210-PAF (the Action), subject to the entry by the United States Bankruptcy Court for the Southern District of Texas, which is handling the Sorrento bankruptcy filing (the Bankruptcy Court), of an order approving the Settlement Agreement (the Settlement Order).
• As settlement consideration, the Company agreed to pay Sorrento and Scilex a total cash payment of $6 million, of which $3.5 million was paid two business days after the date that the Settlement Order was entered by the Bankruptcy Court (the Effective Date), which payment was made on March 18, 2024 and the remaining $2.5 million is to be paid on or before July 1, 2024.
• Additionally, the Company agreed to pay to Plaintiffs royalties of 6% of annual net sales of products developed from drug candidates Epoladerm, Probudur and Envelta until the earlier of the expiration of the last-to-expire valid patent claim of such product and the expiration of any period of regulatory exclusivity for such product.

Stakeholder Impact

• Shareholders face potential dilution from the offering and risks related to the company's financial condition.
• Employees' job security and compensation may be affected by the company's financial performance and ability to secure funding.
• Customers may benefit from the development of new pain management and CNS disorder treatments.
• Suppliers and creditors face risks related to the company's ability to meet its financial obligations.

Next Steps

• The company needs to submit a plan to Nasdaq by May 17, 2024, to regain compliance with minimum stockholders' equity requirements.
• The company will continue to develop its product candidates and seek regulatory approval.
• The company will pay the remaining $2.5 million to Sorrento and Scilex on or before July 1, 2024.
• The company will need to raise additional capital to file its IND for Probudur.

Key Dates

Keywords

offering, pharmaceuticals, warrants, common stock, Virpax, litigation, pre-funded warrants, capital raise, product development, Nasdaq